Back to Search Start Over

Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes

Authors :
Heather J. Bax
Jitesh Chauhan
Chara Stavraka
Aida Santaolalla
Gabriel Osborn
Atousa Khiabany
Melanie Grandits
Jacobo López-Abente
Lais C. G. F. Palhares
Charleen Chan Wah Hak
Alexandra Robinson
Amy Pope
Natalie Woodman
Cristina Naceur-Lombardelli
Sadek Malas
Jack E. M. Coumbe
Mano Nakamura
Roman Laddach
Silvia Mele
Silvia Crescioli
Anna M. Black
Sara Lombardi
Silvana Canevari
Mariangela Figini
Ahmad Sayasneh
Sophia Tsoka
Kevin FitzGerald
Cheryl Gillett
Sarah Pinder
Mieke Van Hemelrijck
Rebecca Kristeleit
Sharmistha Ghosh
Ana Montes
James Spicer
Sophia N. Karagiannis
Debra H. Josephs
Source :
Bax, H, Chauhan, J, Stavraka, C, Santaolalla, A, Osborn, G, Khiabany, A, Grandits, M, Lopez-Abente Muroz, J, Gusmao Ferreira, L C, Chan Wah Hak, C, Robinson, A, Pope, A, Woodman, N, Naceur-Lombardelli, C, Malas, S, Nakamura, M, Coumbe, J E M, Laddach, R, Mele, S, Crescioli, S, Black, A, Lombardi, S, Canevari, S, Figini, M, Sayasneh, A, Tsoka, S, FitzGerald, K, Gillett, C, Pinder, S, Van Hemelrijck, M, Kristeleit, R, Ghosh, S, Montes, A, Spicer, J, Karagiannis, S N & Josephs, D 2022, ' Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes ', British Journal of Cancer . https://doi.org/10.1038/s41416-022-02031-x
Publication Year :
2022
Publisher :
Springer Science and Business Media LLC, 2022.

Abstract

Background Survival rates for ovarian cancer remain poor, and monitoring and prediction of therapeutic response may benefit from additional markers. Ovarian cancers frequently overexpress Folate Receptor alpha (FRα) and the soluble receptor (sFRα) is measurable in blood. Here we investigated sFRα as a potential biomarker. Methods We evaluated sFRα longitudinally, before and during neo-adjuvant, adjuvant and palliative therapies, and tumour FRα expression status by immunohistrochemistry. The impact of free FRα on the efficacy of anti-FRα treatments was evaluated by an antibody-dependent cellular cytotoxicity assay. Results Membrane and/or cytoplasmic FRα staining were observed in 52.7% tumours from 316 ovarian cancer patients with diverse histotypes. Circulating sFRα levels were significantly higher in patients, compared to healthy volunteers, specifically in patients sampled prior to neoadjuvant and palliative treatments. sFRα was associated with FRα cell membrane expression in the tumour. sFRα levels decreased alongside concurrent tumour burden in patients receiving standard therapies. High concentrations of sFRα partly reduced anti-FRα antibody tumour cell killing, an effect overcome by increased antibody doses. Conclusions sFRα may present a non-invasive marker for tumour FRα expression, with the potential for monitoring patient response to treatment. Larger, prospective studies should evaluate FRα for assessing disease burden and response to systemic treatments.

Subjects

Subjects :
Cancer Research
Oncology

Details

ISSN :
15321827 and 00070920
Volume :
128
Database :
OpenAIRE
Journal :
British Journal of Cancer
Accession number :
edsair.doi.dedup.....540f460d63dc952bc739807eae588499
Full Text :
https://doi.org/10.1038/s41416-022-02031-x